Pivotal bioVenture Partners Investment Advisor LLC
Pivotal bioVenture Partners Investment Advisor LLC reported 13 US-listed holdings worth $307.8 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Vaxcyte Inc. (26.9%), Arcutis Biotherapeutics Inc. (10.8%) and Trevi Therapeutics Inc. (10.6%). Against the quarter before, it opened 1 position, added to 3, trimmed 3 and sold out of 1.
The 13 largest of its 13 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +22.1% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- Avalyn Pharma Inc. AVLN$31.8 million
Added to 3
- Trevi Therapeutics Inc. TRVI+188,946 shares · +12%
- Vaxcyte Inc. PCVX+53,045 shares · +4%
- Avalo Therapeutics Inc. AVTX+138,100 shares · +47%
Trimmed 3
- Zenas Biopharma Inc. ZBIO-101,225 shares · -17%
- Oculis Holding AG OCS-174,033 shares · -10%
- Arcutis Biotherapeutics Inc. ARQT-90,609 shares · -7%
Sold out of 1
- Bolt Biotherapeutics Inc. BOLT$172,027 last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Vaxcyte Inc. PCVX | 1.4M | $82.9 million | 26.92% | +53.0K |
| Arcutis Biotherapeutics Inc. ARQT | 1.3M | $33.2 million | 10.78% | -90.6K |
| Trevi Therapeutics Inc. TRVI | 1.7M | $32.5 million | 10.56% | +188.9K |
| Avalyn Pharma Inc. AVLN | 966.8K | $31.8 million | 10.34% | new |
| Evommune Inc. EVMN | 1.9M | $25.6 million | 8.32% | no change |
| Maplight Therapeutics Inc. MPLT | 611.4K | $21.9 million | 7.12% | -1 |
| Oculis Holding AG OCS | 1.5M | $20.9 million | 6.79% | -174.0K |
| Bioage Labs Inc. BIOA | 653.4K | $16.0 million | 5.20% | no change |
| Immunome Inc. IMNM | 732.5K | $15.5 million | 5.04% | no change |
| Zenas Biopharma Inc. ZBIO | 490.8K | $12.5 million | 4.05% | -101.2K |
| Avalo Therapeutics Inc. AVTX | 434.0K | $8.0 million | 2.61% | +138.1K |
| Rallybio Corp. Com RLYB | 300.6K | $4.8 million | 1.56% | no change |
| Recursion Pharmaceuticals in RXRX | 595.5K | $2.2 million | 0.71% | no change |